

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 December 2022 (01.12.2022)



(10) International Publication Number
WO 2022/251868 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) G01N 33/50 (2006.01)

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:
PCT/US2022/072605

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:
27 May 2022 (27.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/202,150 28 May 2021 (28.05.2021) US
63/262,942 22 October 2021 (22.10.2021) US

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **VIGIL NEUROSCIENCE, INC.** [US/US];
One Broadway Suite 07-300, Cambridge, Massachusetts
02142 (US).

(72) Inventors: **LARSON, Kelley C.**; c/o Vigil Neuroscience, Inc., One Broadway Suite 07-300, Cambridge, Massachusetts 02142 (US). **LYNCH, Berkley A.**; c/o Vigil Neuroscience, Inc., One Broadway Suite 07-300, Cambridge, Massachusetts 02142 (US). **FISHER, Richard**; c/o Vigil Neuroscience, Inc., One Broadway Suite 07-300, Cambridge, Massachusetts 02142 (US). **PAPA-PETROPOULOS, Spyridon**; c/o Vigil Neuroscience, Inc., One Broadway Suite 07-300, Cambridge, Massachusetts 02142 (US). **THACKABERRY, Evan Andrew**; c/o Vigil Neuroscience, Inc., One Broadway Suite 07-300, Cambridge, Massachusetts 02142 (US). **MANDELBLAT-CERF, Yael**; c/o Vigil Neuroscience, Inc., One Broadway Suite 07-300, Cambridge, Massachusetts 02142 (US).

(74) Agent: **REID, Andrea L.C.**; c/o Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: TREM2 AGONIST BIOMARKERS AND METHODS OF USE THEREOF

(57) Abstract: The present invention provides a method of treating a condition or disorder associated with microglial dysfunction in a human patient, such as Alzheimer's disease, comprising administering to the patient a TREM2 agonist. In another aspect, the invention provides a method of assaying a biological sample taken from a patient having such a condition, such as Alzheimer's disease, for biomarkers characteristic of microglia activity in order to determine treatment benefit or whether the disease has an increased probability of responding to treatment with a TREM2 agonist.

WO 2022/251868 A1